Stocks · News reference
Needham Maintains Buy on Veradermics, Raises Price Target to $172
Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $164 to $172.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B. Riley Raises Price Target on Veradermics to $204
B. Riley has increased its price target for Veradermics, Incorporated from $170 to $204 while maintaining a 'Buy' rating.
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
Veradermics stock jumped 10% on positive Phase 3 results for its oral hair loss pill, VDPHL01. Read the full efficacy and safety data.
Veradermics shares are trading higher after the company announced that its VDPHL01 met all primary and secondary endpoints. Also, Needham maintained its Buy rating on the stock and raised its price target from $164 to $172.